In Phase C, participants will receive ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment till condition progression or the participants are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit solutions within three days ahead of the initial https://robertn777alw0.wikinewspaper.com/user